Europe — EMA
Nytyka (Nintedanib)
Nintedanib, the active ingredient in Nytyka, is a tyrosine kinase inhibitor presented as a 150 mg capsule for oral use. It is indicated for the treatment of fibrotic lung diseases in adult patients.
Request sourcing
What is Nintedanib?
Nintedanib, the active ingredient in Nytyka, is a tyrosine kinase inhibitor presented as a 150 mg capsule for oral use. It is indicated for the treatment of fibrotic lung diseases in adult patients. GNH USA supplies Nytyka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.
GNH USA supplies Nytyka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.
What is Nintedanib used for?
Nytyka is a tyrosine kinase inhibitor that targets pathways involved in progressive fibrotic disease.
- Idiopathic pulmonary fibrosis: helps slow the decline of lung function. - Systemic sclerosis‑associated interstitial lung disease: reduces the rate of forced vital capacity decline. - Progressive fibrosing interstitial lung disease (PF‑ILD): slows disease progression. - Chronic fibrotic lung disease not otherwise specified: may delay functional decline. - Severe chronic hypersensitivity pneumonitis: supports preservation of lung capacity.
